Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

MEDIFAST INC (MED)

Consumer Cyclical Personal Services
9.90 $
-0.5% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at MEDIFAST INC.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 4 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet
Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap
0.1$B
Shares Outstanding
11Mio.
Float
69.3%
Beta
0.7

Performance

Perf. 1M
-18.60%
Perf. 3M
9.70%
Perf. 6M
-5.10%
YTD Performance (%)
-0.60%
52-Week-High Distance
-34.0%
Perf. 1Y
-22.16%
Perf. 3Y
-87.50%
Perf. 5Y
-95.82%

Valuation

P/E
Forward P/E
12.5
PEG
1.0
P/B
0.6
P/S
0.3
EV/EBITDA
0.3
Price/FCF

Profitability

Gross Margin
70.1%
EBIT Margin
Net Margin
-5.8%
Return on Equity
-9.8%
Return on Assets
-4.3%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
0.1
fortress balance sheet
Altman Z″
13.05
Piotroski
3 out of 9

Growth

Sales Growth Last Quarter
-34.30%
EPS Growth Last Quarter
-87.20%
Sales Growth (Year)
-35.96%
Forward Sales Growth
-8.47%
Forward EPS Growth
67.60%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
1
RS Rating
23
EPS Rating
4
Piotroski
3 out of 9
Fundamental Rating
D (37 out of 100)
fortress balance sheet
Altman Z″
13.05

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 9.90 $
Price Target (average) 12.00 $

The price target sits 21.2% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

3. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-0.67 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Sales Per Quarter ($M)
2024: Q4 · 119.0 $M Q4 2025: Q1 · 115.7 $M Q1 2025: Q2 · 105.6 $M Q2 2025: Q3 · 89.4 $M Q3 2025: Q4 · 75.1 $M Q4 2026: Q1 · 76.0 $M Q1
Earnings Per Share Per Quarter ($)
2024: Q4 · 0.07 $ Q4 2025: Q1 · -0.07 $ Q1 2025: Q2 · 0.22 $ Q2 2025: Q3 · -0.21 $ Q3 2025: Q4 · -1.65 $ Q4 2026: Q1 · -0.19 $ Q1
Net Margin Per Quarter (%)
2024: Q4 · 0.7 % Q4 2025: Q1 · -0.7 % Q1 2025: Q2 · 2.3 % Q2 2025: Q3 · -2.5 % Q3 2025: Q4 · -24.1 % Q4 2026: Q1 · -2.8 % Q1
Operating Cash Flow Per Quarter ($M)
2024: Q4 · -4.9 $M Q4 2025: Q1 · 3.4 $M Q1 2025: Q2 · -3.4 $M Q2 2025: Q3 · 12.1 $M Q3 2025: Q4 · -5.3 $M Q4 2026: Q1 · 0.3 $M Q1
Free Cash Flow Per Quarter ($M)
2024: Q4 · -7.2 $M Q4 2025: Q1 · 1.9 $M Q1 2025: Q2 · -4.8 $M Q2 2025: Q3 · 10.8 $M Q3 2025: Q4 · -6.6 $M Q4 2026: Q1 · -0.8 $M Q1
Sales Growth vs. Year-Ago Quarter (%)
2024: Q4 · -37.7 % Q4 2025: Q1 · -33.8 % Q1 2025: Q2 · -37.4 % Q2 2025: Q3 · -36.2 % Q3 2025: Q4 · -36.9 % Q4 2026: Q1 · -34.3 % Q1
EPS Growth vs. Year-Ago Quarter (%)
2024: Q4 · -86.8 % Q4 2025: Q1 · -109.3 % Q1 2025: Q3 · -299.9 % Q3 2025: Q4 · -2,360.4 % Q4
Price Change in Quarter (%)
2024: Q4 · -7.9 % Q4 2025: Q1 · -23.5 % Q1 2025: Q2 · 4.2 % Q2 2025: Q3 · -2.7 % Q3 2025: Q4 · -21.9 % Q4 2026: Q1 · -4.6 % Q1

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.07 -86.80 119 -37.70 0.70 -5 -7
2025: Q1 -0.07 -109.30 116 -33.80 -0.70 3 2
2025: Q2 0.22 106 -37.40 2.30 -3 -5
2025: Q3 -0.21 -299.90 89 -36.20 -2.50 12 11
2025: Q4 -1.65 -2,360.40 75 -36.90 -24.10 -5 -7
2026: Q1 -0.19 76 -34.30 -2.80 0 -1
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Medifast, Inc. ist über seine Tochtergesellschaften ein Gesundheits- und Wellnessunternehmen, das gewohnheitsbasierte und coachgeführte Lifestyle-Lösungen zur Gewichtsabnahme in den USA anbietet.

Employees380
HeadquartersBaltimore, MD
Websitemedifastinc.com
IPO Date31. Dec 1993

Management

Management
Name Title Birth Year
Nicholas M. Johnson CEO & President 1980
James P. Maloney CPA Chief Financial Officer 1968
Jonathan Barrett MacKenzie VP of Finance & Chief Accounting Officer 1972
Steven Zenker Vice President of Investor Relations
Claudia C. Greninger Chief Human Resources Officer 1974

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?